Veracyte Reports Strong Preliminary 2025 Results and Positive 2026 Revenue Guidance
summarizeSummary
Veracyte reported strong preliminary Q4 and full-year 2025 financial results, including 16% revenue growth, and issued positive 2026 revenue guidance, indicating continued operational strength and future growth.
check_boxKey Events
-
Preliminary 2025 Financials
Veracyte expects to report full-year 2025 total revenue between $515 million and $517 million, representing approximately 16% growth, with testing revenue growing 17% to 18%.
-
Strong Testing Volume Growth
Full-year 2025 testing volume is estimated at approximately 169,700 tests, a 19% increase, driven by 27% growth in Decipher volume and 11% in Afirma volume.
-
Positive 2026 Outlook
The company initiated 2026 total revenue guidance of $570 million to $582 million (10% to 13% growth) and expects adjusted EBITDA margin to remain at 25%.
-
New Product Launches Anticipated
CEO Marc Stapley highlighted anticipated 2026 launches of Prosigna and the TrueMRD platform in the US market, expected to further expand patient reach and financial performance.
auto_awesomeAnalysis
Veracyte announced robust preliminary financial results for Q4 and full-year 2025, demonstrating significant revenue and testing volume growth. The company also provided an optimistic outlook for 2026, projecting continued revenue growth and stable adjusted EBITDA margins, further bolstered by anticipated new product launches. These results suggest strong operational performance and positive momentum for the company's diagnostic offerings.
At the time of this filing, VCYT was trading at $42.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $22.61 to $50.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.